As 2024 drew to a close, Englands NICE finalised its guidance for Mounjaro, recommending its use in the primary care setting, for treating adults with a body mass index (BMI) 35 kg/m2 and at least one weight-related co-morbidity, alongside a reduced-calorie diet and increased exercise, with no restriction on treatment duration, equating to a total eligible population of 3.4 million patients [5]
The decision to scrap the plan by the budget-slashing Trump administration could make things much harder for millions of people with obesity, however
- Increased blood glucose (glucagon)
e51784 (2014)
If youre interested in a structured low-dose approach, Nooms Microdose GLP-1 Rx Program is designed specifically for thatwith medication included, a dedicated titration protocol, and built-in support tools
Muscle quantity is not strength